APEIRON Biologics receives green light for marketing approval of APN311 in the European Union

APEIRON Biologics AG today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of dinutuximab beta (APN311; ch14.18/CHO) for immunotherapy of high risk neuroblastoma.

Press release